Investment
Features
FeesSafety
Academy
More
Pluang+

Compare T1 Energy Inc. Common Stock (TE) vs TG Therapeutics Inc (TGTX) Price & Performance

T1 Energy Inc. Common StockTrade
TG Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

T1 Energy Inc. Common Stock vs TG Therapeutics Inc — how do they compare? T1 Energy Inc. Common Stock trades at $2.71 (market cap $868.55M), while TG Therapeutics Inc trades at $54.48 (market cap $8.32B). The key difference: TG Therapeutics Inc is far larger — about 9.6× T1 Energy Inc. Common Stock's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, T1 Energy Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold T1 Energy Inc. Common Stock for 0 Days and TG Therapeutics Inc for 16 Days on average.

TETGTX
Market Cap
$868.55M$8.32B
Volume
19,771,9341,285,303
Sector
IndustrialsHealth
52-Week High
$12.04$59.06
52-Week Low
$2.72$26.94
Typical Hold Time
0 Days16 Days
Enterprise Value
$1.64B$8.52B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

T1 Energy Inc. Common Stock

T1 Energy (TE) trades at $3.16, down 1.56% today, reflecting ongoing investor caution despite a mixed earnings history. The company shows significant revenue growth from $755M in 2025 to $997M in 2026 but remains deeply unprofitable with a -38.49% net margin. Recent news highlights strategic moves toward vertical integration in solar manufacturing and energy storage, including the G2_Austin facility development and new supply agreements, which are central to its growth narrative.

The investment case hinges on execution of vertical integration and policy tailwinds, offering substantial upside to the $8 consensus target, but high execution risk, persistent losses, and regulatory scrutiny present clear dangers. Analyst sentiment is mixed with a Moderate Buy rating, yet the stock's viability depends heavily on future profitability improvements from 2027 onward.

TG Therapeutics Inc

TG Therapeutics (TGTX) trades at $54.34, down 1.68% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong revenue growth, with 2025 revenue at $616.29 million and net income of $447.18 million, though recent quarterly EPS results missed expectations. Analyst sentiment is overwhelmingly positive, with 11 buy ratings and a consensus price target of $80.50, while recent news highlights Briumvi's market share gains and potential acquisition interest.

The outlook for TGTX is favorable, driven by Briumvi's expanding multiple sclerosis market share and raised 2026 revenue guidance to $950 million. Key risks include ongoing earnings misses, a high EV/EBITDA ratio of 61.15, and a shareholder litigation investigation. Upside potential remains if the company meets future earnings targets and sustains its growth trajectory.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

TE
100% Buy0% Sell
Avg holding period · 0 Days
TGTX

No sentiment data available yet.

About T1 Energy Inc. Common Stock

T1 Energy Inc. manufactures photovoltaic solar modules and cells in US, operating a solar manufacturing facility in Texas acquired from Trina Solar. The company was formerly known as FREYR Battery before rebranding as T1 Energy in 2025 and changing its NYSE ticker from FREY to TE.

Read more on TE →

About TG Therapeutics Inc

TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.

Read more on TGTX →